Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
Type:
Grant
Filed:
May 28, 2012
Date of Patent:
June 14, 2016
Inventors:
Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
Type:
Grant
Filed:
December 23, 2014
Date of Patent:
June 14, 2016
Assignee:
ALDEYRA THERAPEUTICS, INC.
Inventors:
Thomas A. Jordan, John E. Dowling, John Clifford Chabala
Abstract: The invention provides a method for treating viral infections and coinfections through the use of inhibitory agents that prevent a unique viral structural protein motifs from binding to host proteins from the clathrin adaptor proteins family and subsequently preventing viral replication.
Type:
Grant
Filed:
December 6, 2012
Date of Patent:
June 14, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from Ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.
Type:
Grant
Filed:
February 29, 2012
Date of Patent:
June 14, 2016
Assignee:
KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
Inventors:
Joung Han Yim, Il Chan Kim, Se Jong Han, Hyoung Seok Lee, Hari Datta Bhattarai, Su-Geun Yang, Lee Don Hang
Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
Type:
Grant
Filed:
November 24, 2014
Date of Patent:
June 7, 2016
Assignees:
Dana-Farber Cancer Institute, Inc., University of Miami
Abstract: The present invention relates to a crosslinked gelatin support, in which a surface of a crosslinked gelatin is negatively charged and has a zeta potential in ethanol of from ?3 to ?50 mV, and a support for controlled release of a physiologically active substance, including: the crosslinked gelatin support; and a physiologically active substance adsorbed and retained on and/or inside the crosslinked gelatin support.
Abstract: The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives.
Type:
Grant
Filed:
February 15, 2011
Date of Patent:
May 31, 2016
Assignee:
The University of Wolverhampton
Inventors:
Christopher John Perry, Iain Douglas Nicholl
Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-xL.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
May 24, 2016
Assignee:
AbbVie Inc.
Inventors:
Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Type:
Grant
Filed:
September 18, 2013
Date of Patent:
May 24, 2016
Assignee:
Auspex Pharmaceuticals, Inc.
Inventors:
Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
Abstract: The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising thymol, selected propen-2-yl-methyl-cyclohexanols, and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants.
Type:
Grant
Filed:
December 5, 2012
Date of Patent:
May 17, 2016
Assignee:
Dow Global Technologies LLC
Inventors:
Robert J. Cornmell, Megan A. Diehl, Stephen Golding, John R. Harp, Ian P. Stott, Katherine M. Thompson, Carol L. Truslow
Abstract: The invention discloses a technical process to prepare a self-reinforced starch composite used to produce capsules. This composite is made by uniformly mixing the matrix phase and the particulate reinforced phase at a proper proportion, the former being one or a combination of the starches selected from the group consisting of oxidized starch, cationic starch and esterified starch; and the latter, cross-linked starch or starch nanocrystals. This composite is processed into the forms of granules, films, or sheets by extrusion method and these different forms of the composite can be used to replace the gelatin as the raw material of capsules because its barrier property, processability, and mechanical properties are significantly improved.
Type:
Grant
Filed:
October 21, 2014
Date of Patent:
May 17, 2016
Assignee:
Zhongshan Capsule Starch Material Technology Co., Ltd.
Abstract: The present invention provides a combination product comprising a component A and a component B, wherein component A is a compound of formula (I) wherein A1, A2, L, p, R1, R2, R3, R4 and R5 are as defined in claim 1 and component B is a further therapeutic agent; wherein the combination product is for use in a method of therapeutic treatment.
Abstract: The present invention refers to an active moiety of Paullinia cupana with enhanced activity against fatigue. Particularly related to cancers, and its manufacturing process, pharmaceutical compositions and drugs containing the same. Another object of the present invention is a method for treating fatigue, particularly related to cancers.
Type:
Grant
Filed:
March 30, 2012
Date of Patent:
May 10, 2016
Inventors:
Luiz Francisco Pianowski, João Batista Calixto, Auro Del Giglio
Abstract: Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis.
Abstract: Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity.
Type:
Grant
Filed:
February 5, 2014
Date of Patent:
May 3, 2016
Assignee:
RAPTOR PHARMACEUTICALS INC.
Inventors:
Thomas E. Daley, Elizabeth C. Squiers, Kin-Hung Peony Yu
Abstract: Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.
Type:
Grant
Filed:
May 21, 2014
Date of Patent:
April 26, 2016
Assignee:
NEKTAR THERAPEUTICS
Inventors:
Anthony O. Chong, Seoju Lee, Bhalchandra V. Joshi, Brian Bray, Shaoyong Nie, Patrick L. Spence
Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.
Abstract: The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of cancer.
Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
Type:
Grant
Filed:
March 26, 2014
Date of Patent:
March 22, 2016
Assignee:
AbbVie Inc.
Inventors:
R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh